PHARMACOLOGICAL
MANAGEMENT OF
DIABETES
,PHARMACOLOGICAL MANAGEMENT
Includes:
Oral glucose lowering agents (OGLAS)
Insulin
Combination OGLAS and insulin
, TARGETS OF CURRENT DRUGS
IN THE TREATMENT OF T2DM
GLP-1 analog (exenatide
injectable) DPP-4 inhibitors
Improves glucose-dependent insulin Prolong GLP-1 action, stimulate
secretion, suppresses glucagon insulin secretion, suppress glucagon
secretion, slows gastric emptying release
Biguanide (metformin) Thiazolidinediones
Decreases hepatic Increase glucose uptake
glucose production and in skeletal muscle and
increases glucose uptake decrease lipolysis in
adipose tissue
Sulfonylureas
Increase insulin
secretion from
pancreatic -cells -glucosidase inhibitors
Delay intestinal
Meglitinides carbohydrate absorption
Increase insulin secretion
from pancreatic -cells
DP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; T2DM=type 2 diabetes mellitus
dapted from Cheng AY, Fantus IG. CMAJ 2005; 172: 213-226.
MANAGEMENT OF
DIABETES
,PHARMACOLOGICAL MANAGEMENT
Includes:
Oral glucose lowering agents (OGLAS)
Insulin
Combination OGLAS and insulin
, TARGETS OF CURRENT DRUGS
IN THE TREATMENT OF T2DM
GLP-1 analog (exenatide
injectable) DPP-4 inhibitors
Improves glucose-dependent insulin Prolong GLP-1 action, stimulate
secretion, suppresses glucagon insulin secretion, suppress glucagon
secretion, slows gastric emptying release
Biguanide (metformin) Thiazolidinediones
Decreases hepatic Increase glucose uptake
glucose production and in skeletal muscle and
increases glucose uptake decrease lipolysis in
adipose tissue
Sulfonylureas
Increase insulin
secretion from
pancreatic -cells -glucosidase inhibitors
Delay intestinal
Meglitinides carbohydrate absorption
Increase insulin secretion
from pancreatic -cells
DP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; T2DM=type 2 diabetes mellitus
dapted from Cheng AY, Fantus IG. CMAJ 2005; 172: 213-226.
